Positive Outlook for Cullinan Management: Buy Rating Driven by Promising Clinical Data and Strategic Collaborations

William Blair analyst Matt Phipps has reiterated their bullish stance on CGEM stock, giving a Buy rating on May 27.

Matt Phipps has given his Buy rating due to a combination of factors including the promising clinical data from Cullinan Management’s zipalertinib, which targets EGFR exon 20 insertion mutations in non-small-cell lung cancer. The drug’s oral convenience and favorable tolerability are seen as potential advantages for its adoption in frontline treatment, despite its initial approval being anticipated for second-line use.
Additionally, the collaboration with Taiho Oncology provides a nondilutive capital source, supporting further development of Cullinan’s pipeline programs. The upcoming data from the REZILIENT2 study and the anticipated completion of enrollment in the REZILIENT3 study are also key milestones that could enhance investor interest and drive stock performance. These elements collectively underpin the positive outlook and the Buy rating for Cullinan Management’s stock.

In another report released on May 27, JonesTrading also maintained a Buy rating on the stock with a $34.00 price target.